DGAP-News: Presse Release: 4SC hires experienced pharmaceutical manager and oncology expert

DGAP-News: Presse Release: 4SC hires experienced pharmaceutical manager and 
oncology expert

DGAP-News: 4SC AG / Key word(s): Change of Personnel
Presse Release: 4SC hires experienced pharmaceutical manager and
oncology expert

03.07.2014 / 07:30

---------------------------------------------------------------------

Press release

4SC hires experienced pharmaceutical manager and oncology expert

Planegg-Martinsried, Germany, 3 July 2014 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today announced that Dr
Erich Enghofer has joined 4SC in June 2014 in the newly created position of
Executive Vice President Oncology and Haematology thus further
strengthening the company's expertise. The highly experienced pharma
manager and oncology expert will primarily advance the strategic marketing
of 4SC's main product resminostat in its further development toward market
approval in the liver cancer indication. In this connection, Dr Enghofer
will further strengthen 4SC's positioning and products vis-à-vis potential
pharmaceutical partners, strategic and clinical opinion leaders and
investors, and also support the company in its partnering activities in the
field of business development.

Dr Enghofer has more than 30 years of experience in the pharmaceutical
industry with a focus on oncology, during which he held various management
and executive positions at Bayer, Medac Schering Onkologie, Amgen,
Cyanamid-Lederle and Klinge Pharma (now Astellas). For the last nine years,
he was head of the Business Unit Oncology (Haematology-Oncology since 2011)
at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this
function, he was instrumental, among other things, in the attainment of
market approval of the small molecule anti-cancer drug sorafenib
(Nexavar(R)) in the liver cancer indication and the drug's market success
in Germany. Dr Enghofer was a Board member of Deutsche Krebsgesellschaft
(DKG, the German Cancer Society) until May 2014 and is a member of various
high-profile professional organisations such as the German Association for
Haematology and Oncology (DGHO), the American Society of Clinical Oncology
(ASCO), the American Society of Hematology (ASH) and the American
Association for the Advancement of Science (AAAS).

Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich
Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast
expertise in the field of oncology, especially with the drug sorafenib for
treating liver cancer, will further strengthen our team and is most welcome
- especially for positioning our compound resminostat as a new potential
liver cancer therapy and in our ongoing preparations for a Phase II trial
in this indication. Dr Enghofer will also provide crucial support to 4SC in
the expansion of a partner network to key opinion leaders and
pharmaceutical companies, as well as in the business development process."

Dr Erich Enghofer commented: "I am very much looking forward to working in
such a dynamic biotechnology company as 4SC, which has developed a
promising and innovative approach for the liver cancer indication with
resminostat. I have been following the company's activities and product
developments, especially resminostat, for several years now. Liver cancer
is the fifth most common type of cancer worldwide and the third most
frequent tumour-related cause of death. The number of new cases has been
rising sharply over the recent years, giving rise to a high unmet medical
need. My goal is to make a contribution to attaining market approval for
resminostat so as to make it available for patients as quickly as
possible."

Ends

About 4SC 

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a
headcount of 64 employees (55 FTEs) at 31 March 2014. 4SC AG has been
listed on the Prime Standard of the Frankfurt Stock Exchange since December
2005.

Cautionary statement regarding forward-looking statements 
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG 
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services 
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

The Trout Group 
Chad Rubin 
crubin(at)troutgroup.com, Tel.: +1-646-378-2947


End of Corporate News

---------------------------------------------------------------------

03.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     4SC AG                                                 
             Am Klopferspitz 19a                                    
             82152 Martinsried                                      
             Germany                                                
Phone:       +49 (0)89 7007 63-0                                    
Fax:         +49 (0)89 7007 63-29                                   
E-mail:      public@4sc.com                                         
Internet:    www.4sc.de                                             
ISIN:        DE0005753818                                           
WKN:         575381                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
276364 03.07.2014                                                      
 
Press spacebar to pause and continue. Press esc to stop.